[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369786-105":59,"doc-detail-369786-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","slamf1-expression-in-breast-cancer-cells-delays-tumor-growth-in-vivo","SLAMF1 expression in breast cancer cells delays tumor growth in vivo","","SLAMF1 expression is investigated as a potential modulator of tumor immunity in breast cancer. SLAMF1 levels are confirmed in breast cancer tissues using tissue microarrays, then quantified in triple-negative breast cancer (TNBC) cells by flow cytometry and real-time PCR. Clinical dataset analysis links higher SLAMF1 with improved overall survival, and shows radiation-associated increases in SLAMF1. In mice bearing 4T1-SLAMF1 overexpressing tumors, SLAMF1 drives strong CD8+ T-cell infiltration and markedly reduces tumor growth, supporting SLAM-based targeted immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/slamf1-expression-in-breast-cancer-cells-delays-tumor-growth-in-vivo/369786/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/slamf1-expression-in-breast-cancer-cells-delays-tumor-growth-in-vivo/369786.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus regarding SLAMF1 in breast cancer?","Question",{"text":112,"@type":113},"The study evaluates whether SLAMF1 expression in tumors influences immune responses and tumor growth, particularly in triple-negative breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was SLAMF1 expression measured in breast cancer tissues and TNBC cells?",{"text":117,"@type":113},"SLAMF1 expression in breast cancer tissues was confirmed using tissue microarray analysis, while TNBC cells were analyzed using flow cytometry and real-time PCR.",{"name":119,"@type":110,"acceptedAnswer":120},"What effect did SLAMF1 overexpression have in the mouse 4T1 tumor model?",{"text":121,"@type":113},"SLAMF1 overexpression triggered strong infiltrating CD8+ T-cell responses and significantly reduced tumor growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369786,1790876305,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSLAMF1 expression in breast cancer cells delays tumor growth in vivo  \nKyung-Hee Song, Seung-Youn Jung, Jeong-In Park, Dong-Hyeon Lee, Jiyeon Ahn, Sang-Gu Hwang & Jie-Young Song􀀍  \nSignaling lymphocytic activation molecule (SLAM) family receptors are widely expressed on immune cells, often acting as self-ligands and playing crucial roles in cellular communication and adhesion, thereby modulating immune responses. Several studies have demonstrated that SLAM family receptors are associated with potential immune checkpoints onT cells and play a role in tumor immunity in various cancers. However, the effect of SLAMF1 expression in tumors has been rarely investigated. Here, we confirmed SLAMF1 expression using tissue microarray analysis in breast cancer tissues with diverse pathological characteristics and subtypes. Additionally, SLAMF1 expression in triple-negative breast cancer (TNBC) cells was analyzed using flow cytometry and real-time PCR. Public clinical data analysis suggests that a positive correlation exists between SLAMF1 expression and overall survival and that SLAMF1 levels are slightly increased in patients with breast cancer who received radiation therapy. Similarly, when TNBC cells were irradiated, SLAMF1 expression specifically increased compared to that in non-irradiated cells. To study the biological function of SLAMF1 in mice, we established 4T1-SLAMF1 overexpressing a stable cell line. In the 4T1 syngenetic tumor model, SLAMF1 overexpression triggered strong infiltrating-CD8+ T cell responses and significantly reduced the tumor growth. Our results provide clear evidence for SLAMF1 expression in breast cancer and provide insights into the recent advances in SLAM-based targeted immunotherapies.  \nKeywords Breast cancer, Immune checkpoint, Signaling lymphocytic activation molecule (SLAM) family 1 (CD150), Cancer immunotherapy  \nBreast cancer is the most common cancer diagnosed in females worldwide and is a leading cause of mortality and morbidity1. This heterogeneous disease is characterized by extensive molecular alterations that drive invasion and metastasis2,3. Various studies have identified numerous gene mutations in breast cancer cells and categorized them into four subtypes in clinical practice based on immunohistochemical results: luminal A, luminal B, epidermal growth factor receptor 2 (HER2)-enriched, and triple-negative breast cancer (TNBC) . Luminal A is characterized by high estrogen receptor (ER), progesterone receptor (PR)-positive, and HER2-negative, which indicates slower cell growth, better prognosis, and better responses to hormon therapy. While luminal B are also hormone receptor-positive but can be either HER2 positive or negative, and often more aggressive than luminal A. It indicating faster cell growth and may be treated with hormon therapy and chemotherapy. HER2-enriched cancer have high levels of HER2, which are often more aggressive but can benefit from HER2-targeted therapy. TNBC dose not express ER, PR, and HER2 and accounts for 15–20% of breast cancer cases4. Despite the lack of drug-targetable receptors and an overall poorer prognosis5there is no specific treatment strategies for TNBC. Currently, TNBC is managed with conventional treatment, including systemic therapy and locoregional therapy, such as surgery and radiation therapy (RT) . However, the cure rate of TNBC is low due to significant toxicity, relapse, or treatment refractoriness, highlighting the urgent need for developing innovative therapeutic strategies using predictive biomarkers for TNBC.  \nCancer immunotherapy has recently emerged as a ground-breaking advancement in oncology. Clinical trials conducted between 2010 and the present have demonstrated the remarkable antitumor activity of diverse immunotherapeutic approaches, including immune checkpoint inhibitors (ICIs) and adoptive cellular therapies, across a range of cancer types. Although b","cbCais24KNHio5Q1","https://ap.wps.com/l/cbCais24KNHio5Q1","pdf",2500437,12,"English","# Background\n## Breast cancer subtypes and TNBC challenges\n## Immunotherapy and immune checkpoint inhibition\n# SLAMF1 and study design\n## SLAMF1 expression in tissues and TNBC cells\n## Analysis of clinical correlations and radiation effects\n## 4T1-SLAMF1 mouse model and CD8+ T-cell responses","[{\"question\":\"What is the main focus regarding SLAMF1 in breast cancer?\",\"answer\":\"The study evaluates whether SLAMF1 expression in tumors influences immune responses and tumor growth, particularly in triple-negative breast cancer.\"},{\"question\":\"How was SLAMF1 expression measured in breast cancer tissues and TNBC cells?\",\"answer\":\"SLAMF1 expression in breast cancer tissues was confirmed using tissue microarray analysis, while TNBC cells were analyzed using flow cytometry and real-time PCR.\"},{\"question\":\"What effect did SLAMF1 overexpression have in the mouse 4T1 tumor model?\",\"answer\":\"SLAMF1 overexpression triggered strong infiltrating CD8+ T-cell responses and significantly reduced tumor growth.\"}]","SLAMF1 expression in breast cancer cells delays tumor growth in vivo | PDF",1790184542]